Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood blood.2025031313.

https://doi.org/10.1182/blood.2025031313

Published: 2025

Includes: Supplemental data

Journal Articles

Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation

Blood (2025) 146 (Supplement 1): 2494.

https://doi.org/10.1182/blood-2025-2494

Published: 2025

Journal Articles

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

Blood (2025) 146 (Supplement 1): 514.

https://doi.org/10.1182/blood-2025-514

Published: 2025

Journal Articles

FOXP3 and helios expressing CD4+ T conventional cells are a regulatory-like subset that is induced after orca-T allogeneic immunotherapy

Cameron Bader, Scott Killian, Bettina Iliopoulou, Pin-I Chen, Shiva Pathak, Xuhuai Ji, Nate Fernhoff, Kent Jensen, Robert Negrin, Everett Meyer

Blood (2025) 146 (Supplement 1): 822.

https://doi.org/10.1182/blood-2025-822

Published: 2025

Journal Articles

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Blood (2025) 146 (Supplement 1): 111.

https://doi.org/10.1182/blood-2025-111

Published: 2025

Journal Articles

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

Blood (2025) 146 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2025-2525

Published: 2025

Journal Articles

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Blood (2025) 146 (Supplement 1): 671.

https://doi.org/10.1182/blood-2025-671

Published: 2025

Journal Articles

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

Blood (2025) 146 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2025-4159

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Journal Articles

Integrative single-cell multi-omic and functional profiling of human bone marrow regulatory T cells to enhance GVHD-preventive cell therapies

Jessica Diarra, Cameron Bader, Daniel Ho, Trevor Bruce, Kent Jensen, Everett Meyer, Sean Bendall

Blood (2025) 146 (Supplement 1): 5916.

https://doi.org/10.1182/blood-2025-5916

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease

Blood (2025) 146 (Supplement 1): 586.

https://doi.org/10.1182/blood-2025-586

Published: 2025

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

Safer HLA mismatch transplantation

Everett Meyer

Blood (2020) 136 (13): 1472–1474.

https://doi.org/10.1182/blood.2020006922

Published: 2020

Journal Articles

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Michael A. Spinner, MD, Marcelo Fernandez Vina, PhD, Linda Elder, BA, Sally Arai, MD, Laura Johnston, MD, Everett Meyer, MD PhD, David Miklos, MD PhD, Lori Muffly, MD, Robert S. Negrin, MD, Judith Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Samuel Strober, MD, Robert Lowsky, MD, Andrew R. Rezvani, MD

Blood (2016) 128 (22): 4669.

https://doi.org/10.1182/blood.V128.22.4669.4669

Published: 2016

Journal Articles

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Ajib Salem, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Penter Livius, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, MD, Michael Lübbert, MD, Ralph Wäsch, MD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Omid Shah, MD, Robert S. Negrin, MD, Mats Brune, MD PhD, Alexandros Spyridonidis, MD PhD, Annette Schmitt-Graeff, MD, Walter J.F.M. van der Velden, MD PhD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MD PhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Jakob R. Passweg, Joerg Halter, MD, Gérard Socié, MD PhD, Dietrich W. Beelen, Prof. Dr. MD, Christian Peschel, MD, Andreas Neubauer, Jürgen Finke, Justus Duyster, MD, Nikolas von Bubnoff, MD

Blood (2016) 128 (22): 4561.

https://doi.org/10.1182/blood.V128.22.4561.4561

Published: 2016

Journal Articles

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Lori S. Muffly, MDMS, Kevin Sheehan, PhD, Randall Armstrong, Keri Tate, PhD, Cynthia Tudisco, Andrew R. Rezvani, MD, David Miklos, MD PhD, Sally Arai, MD, Judith Shizuru, MD PhD, Laura Johnston, Everett Meyer, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Robert S Negrin, MD, Sam Strober, Robert Lowsky, MD

Blood (2016) 128 (22): 4615.

https://doi.org/10.1182/blood.V128.22.4615.4615

Published: 2016

Journal Articles

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Laura Johnston, MD, Randall Armstrong, Jeanette Baker, PhD, Bita Sahaf, Joanne Otani, Keri Tate, PhD, Cynthia Tudisco, Kevin Sheehan, PhD, Everett Meyer, MD PhD, David Miklos, MD PhD, Robert S. Negrin, MD

Blood (2016) 128 (22): 385.

https://doi.org/10.1182/blood.V128.22.385.385

Published: 2016

Journal Articles

The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Facilitate Conventional T Cell and Treg Control of GvHD and Tissue Tolerance in Murine Models

Antonio Pierini, MD, Bettina Iliopoulou, PhD, Heshan Peiris, PhD, Magdiel Perez Cruz, PhD, Jeanette Baker, PhD, Katie Hsu, PhD, William Strober, Ping-Ping Zheng, PhD, Tom Erkers, PhD, Aaron Ring, MD PhD, Andrea Velardi, Robert S. Negrin, MD, Seung Kim, MD PhD, Everett Meyer, MD PhD

Blood (2016) 128 (22): 3355.

https://doi.org/10.1182/blood.V128.22.3355.3355

Published: 2016

Journal Articles

TNF-α priming enhances CD4 + FoxP3 + regulatory T-cell suppressive function in murine GVHD prevention and treatment

Antonio Pierini, William Strober, Caitlin Moffett, Jeanette Baker, Hidekazu Nishikii, Maite Alvarez, Yuqiong Pan, Dominik Schneidawind, Everett Meyer, Robert S. Negrin

Blood (2016) 128 (6): 866–871.

https://doi.org/10.1182/blood-2016-04-711275

Published: 2016

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

FOXP3 and helios expressing CD4+ T conventional cells are a regulatory-like subset that is induced after orca-T allogeneic immunotherapy

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Integrative single-cell multi-omic and functional profiling of human bone marrow regulatory T cells to enhance GVHD-preventive cell therapies

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Safer HLA mismatch transplantation

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Facilitate Conventional T Cell and Treg Control of GvHD and Tissue Tolerance in Murine Models

TNF-α priming enhances CD4 + FoxP3 + regulatory T-cell suppressive function in murine GVHD prevention and treatment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only